Welcome to our dedicated page for Gossamer Bio news (Ticker: GOSS), a resource for investors and traders seeking the latest updates and insights on Gossamer Bio stock.
Gossamer Bio, Inc. (NASDAQ: GOSS) is a late-stage, clinical biopharmaceutical company centered on the development and commercialization of seralutinib for pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH‑ILD). The GOSS news feed on Stock Titan brings together company announcements, scientific updates, financial disclosures, and corporate developments that shape the investment and clinical narrative around its pulmonary hypertension programs.
News items for Gossamer Bio frequently cover progress in its registrational Phase 3 trials, including the PROSERA Study in PAH and the SERANATA Study in PH‑ILD. Investors and observers can follow updates on enrollment milestones, planned timelines for topline data, and key clinical endpoints such as six‑minute walk distance (6MWD), time to clinical worsening, and lung function measures. Scientific conference coverage, such as presentations at the European Respiratory Society (ERS) Congress, provides additional context on seralutinib’s mechanistic and translational data.
The GOSS news stream also reflects Gossamer Bio’s broader corporate and pipeline activities. This includes quarterly financial results and business updates, collaboration news with the Chiesi Group, stockholder meeting outcomes, and announcements related to its option agreement to acquire Respira Therapeutics and the investigational inhaled vardenafil candidate RT234. Regular disclosures of employment inducement stock option grants highlight hiring and equity compensation practices under Nasdaq Listing Rule 5635(c)(4).
By monitoring Gossamer Bio news on Stock Titan, readers can track how clinical data, regulatory milestones, scientific presentations, financial performance, and strategic transactions interact within the company’s focused pulmonary hypertension strategy. This page is intended as a central hub for GOSS-related headlines and press releases, helping users follow the evolution of its late-stage programs over time.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Gossamer Bio reported its financial results for Q4 and full year 2022, highlighting a net loss of $55.8 million or $0.59 per share in Q4, and a full-year net loss of $229.4 million or $2.71 per share. Cash, cash equivalents, and marketable securities were $256 million, expected to sustain operations into the second half of 2024. The company plans to initiate a Phase 3 clinical trial for Seralutinib (GB002) in pulmonary arterial hypertension in H2 2023, while enrollment in the Phase 1b/2 GB5121 CNS study is paused.
Gossamer Bio announced promising topline results from the TORREY Phase 2 study of seralutinib in treating pulmonary arterial hypertension (PAH). The primary endpoint, change in pulmonary vascular resistance (PVR) at Week 24, was met with a statistically significant P-value of 0.0310. Secondary endpoints also favored seralutinib, particularly in patients classified as WHO Functional Class III, showing a 21% reduction in PVR and a 37-meter improvement in six-minute walk distance (6MWD). Seralutinib exhibited a favorable safety profile, with most adverse events being mild to moderate.
Gossamer Bio reported its financial results for Q3 2022, highlighting a cash position of $304.4 million as of September 30, 2022. The Phase 2 TORREY Study for Seralutinib, targeting pulmonary arterial hypertension, is on schedule for topline results by December 2022. R&D expenses rose to $44.5 million from $43.2 million year-over-year, while G&A expenses decreased to $11.5 million. The net loss narrowed to $59.4 million or $0.65 per share compared to the previous year. Gossamer expects existing resources to fund operations into Q2 2024.
Gossamer Bio, Inc. (Nasdaq: GOSS) reported financial results for Q2 2022, highlighting a net loss of $56.5 million ($0.74 per share), improved from $59.8 million ($0.80 per share) in Q2 2021. As of June 30, 2022, the company had $342 million in cash and equivalents, bolstered by a $120 million private placement in July 2022. Upcoming milestones include topline data from the Phase 2 TORREY Study on seralutinib, expected by year-end, and the initiation of a Phase 3 clinical program in Q3 2023. Additionally, the first patient has been dosed in the Phase 1b/2 STAR CNS Study for GB5121.
Gossamer Bio, Inc. (NASDAQ: GOSS) announced a private placement of approximately 16.6 million shares at $7.21 each, expecting gross proceeds of around $120 million before expenses. This financing, closing on July 15, 2022, involves new and existing institutional investors, all participating under lock-up agreements. The funds will support the seralutinib program and other R&D efforts, with sufficient funds anticipated to cover operating expenses into mid-2024. The company plans to file for resale registration with the SEC, as the shares have not been registered under the Securities Act.
Gossamer Bio, Inc. (NASDAQ: GOSS) announces the publication of preclinical data on seralutinib for pulmonary arterial hypertension (PAH) in the European Respiratory Journal. The article highlights seralutinib's potential efficacy in treating PAH, with expectations for topline results from the Phase 2 TORREY Study to be released in Q4 this year. CEO Faheem Hasnain expressed enthusiasm for the recognition of their work in a prestigious journal, signaling a pivotal moment for the company's ongoing research.